Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.
Identifieur interne : 000207 ( Main/Exploration ); précédent : 000206; suivant : 000208Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.
Auteurs : Gaston De Serres [Canada] ; Isabelle Rouleau [Canada] ; Danuta M. Skowronski [Canada] ; Manale Ouakki [Canada] ; Kevin Lacroix [Canada] ; Fernand Bédard [Canada] ; Eveline Toth [Canada] ; Monique Landry [Canada] ; Nicolas Dupré [Canada]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Association médicamenteuse (MeSH), Enfant (MeSH), Europe (épidémiologie), Facteurs de risque (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Paresthésie (induit chimiquement), Paresthésie (épidémiologie), Polysorbates (administration et posologie), Polysorbates (effets indésirables), Québec (épidémiologie), Sous-type H1N1 du virus de la grippe A (immunologie), Squalène (administration et posologie), Squalène (effets indésirables), Sujet âgé (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), alpha-Tocophérol (administration et posologie), alpha-Tocophérol (effets indésirables), Études cas-témoins (MeSH).
- MESH :
- administration et posologie : Polysorbates, Squalène, Vaccins antigrippaux, alpha-Tocophérol.
- effets indésirables : Polysorbates, Squalène, Vaccins antigrippaux, alpha-Tocophérol.
- immunologie : Sous-type H1N1 du virus de la grippe A.
- induit chimiquement : Paresthésie.
- prévention et contrôle : Grippe humaine.
- virologie : Grippe humaine.
- épidémiologie : Europe, Paresthésie, Québec.
- Adolescent, Adulte, Adulte d'âge moyen, Association médicamenteuse, Enfant, Facteurs de risque, Femelle, Humains, Jeune adulte, Mâle, Sujet âgé, Études cas-témoins.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Case-Control Studies (MeSH), Child (MeSH), Drug Combinations (MeSH), Europe (epidemiology), Female (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza, Human (prevention & control), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Paresthesia (chemically induced), Paresthesia (epidemiology), Polysorbates (administration & dosage), Polysorbates (adverse effects), Quebec (epidemiology), Risk Factors (MeSH), Squalene (administration & dosage), Squalene (adverse effects), Young Adult (MeSH), alpha-Tocopherol (administration & dosage), alpha-Tocopherol (adverse effects).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Polysorbates, Squalene, alpha-Tocopherol.
- chemical , adverse effects : Influenza Vaccines, Polysorbates, Squalene, alpha-Tocopherol.
- chemical : Drug Combinations.
- geographic , epidemiology : Europe, Quebec.
- chemically induced : Paresthesia.
- epidemiology : Paresthesia.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Case-Control Studies, Child, Female, Humans, Male, Middle Aged, Risk Factors, Young Adult.
Abstract
BACKGROUND
Paresthesia was the third-most-common adverse event following immunization (AEFI) with 2009 monovalent AS03-adjuvanted A(H1N1)pdm09 vaccine in Quebec, Canada and was also frequently reported in Europe. This study assessed clinical features and risk factors associated with this unexpected AEFI.
METHODS
Reports to the passive surveillance system were summarized. A case-control study was conducted to assess risk factors and additional investigations were undertaken among cases with symptoms persisting ≥12 months.
RESULTS
There were 328 reports of paresthesia affecting the vaccinated arm (58%), but also face (45%), lower limbs (40%) and back/thorax (23%) with numbness but also muscle weakness (61%), motor impairment (61%), generalized myalgia (37%), visual (14%) and/or speech effects (15%). Reporting rate was highest in women of reproductive age, peaking at 30-39 years-old (28/100,000 doses administered) and exceeding that of men of the same age (7/100,000 doses) by 4-fold. Median time to onset was 2h. Symptoms subsided within one week in 37% but lasted ≥6 months in 26%. No consistent or objective neurological findings were identified. Risk was increased with allergy history, respiratory illness the day of vaccination, depressive symptoms and family history of pulmonary disease, but decreased with physical activity the day of vaccination, and regular weekly alcohol consumption.
CONCLUSION
Paresthesia following 2009 pandemic vaccine receipt lasted several weeks and included other motor-sensory disturbances in an important subset of patients. Although it does not correspond with known neurological disease, and causality remains uncertain, further investigation is warranted to understand the nature and frequency of paresthesia as a possible AEFI with influenza vaccines.
DOI: 10.1016/j.vaccine.2015.07.028
PubMed: 26209839
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.</title><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name><affiliation wicri:level="4"><nlm:affiliation>Institut national de santé publique du Québec, Quebec, Canada; Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec , Canada. Electronic address: gaston.deserres@inspq.qc.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institut national de santé publique du Québec, Quebec, Canada; Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec </wicri:regionArea><orgName type="university">Université Laval</orgName><placeName><settlement type="city">Québec (ville)</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Rouleau, Isabelle" sort="Rouleau, Isabelle" uniqKey="Rouleau I" first="Isabelle" last="Rouleau">Isabelle Rouleau</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Ministère de la santé et des services sociaux du Québec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name><affiliation wicri:level="3"><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>British Columbia Centre for Disease Control, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="Ouakki, Manale" sort="Ouakki, Manale" uniqKey="Ouakki M" first="Manale" last="Ouakki">Manale Ouakki</name><affiliation wicri:level="1"><nlm:affiliation>Institut national de santé publique du Québec, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institut national de santé publique du Québec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Lacroix, Kevin" sort="Lacroix, Kevin" uniqKey="Lacroix K" first="Kevin" last="Lacroix">Kevin Lacroix</name><affiliation wicri:level="1"><nlm:affiliation>CHU de Québec, Quebec , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CHU de Québec, Quebec </wicri:regionArea><wicri:noRegion>Quebec </wicri:noRegion></affiliation></author><author><name sortKey="Bedard, Fernand" sort="Bedard, Fernand" uniqKey="Bedard F" first="Fernand" last="Bédard">Fernand Bédard</name><affiliation wicri:level="1"><nlm:affiliation>CHU de Québec, Quebec , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CHU de Québec, Quebec </wicri:regionArea><wicri:noRegion>Quebec </wicri:noRegion></affiliation></author><author><name sortKey="Toth, Eveline" sort="Toth, Eveline" uniqKey="Toth E" first="Eveline" last="Toth">Eveline Toth</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Ministère de la santé et des services sociaux du Québec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Ministère de la santé et des services sociaux du Québec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Dupre, Nicolas" sort="Dupre, Nicolas" uniqKey="Dupre N" first="Nicolas" last="Dupré">Nicolas Dupré</name><affiliation wicri:level="4"><nlm:affiliation>Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec </wicri:regionArea><orgName type="university">Université Laval</orgName><placeName><settlement type="city">Québec (ville)</settlement><region type="state">Québec</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26209839</idno><idno type="pmid">26209839</idno><idno type="doi">10.1016/j.vaccine.2015.07.028</idno><idno type="wicri:Area/Main/Corpus">000205</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000205</idno><idno type="wicri:Area/Main/Curation">000205</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000205</idno><idno type="wicri:Area/Main/Exploration">000205</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.</title><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name><affiliation wicri:level="4"><nlm:affiliation>Institut national de santé publique du Québec, Quebec, Canada; Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec , Canada. Electronic address: gaston.deserres@inspq.qc.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institut national de santé publique du Québec, Quebec, Canada; Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec </wicri:regionArea><orgName type="university">Université Laval</orgName><placeName><settlement type="city">Québec (ville)</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Rouleau, Isabelle" sort="Rouleau, Isabelle" uniqKey="Rouleau I" first="Isabelle" last="Rouleau">Isabelle Rouleau</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Ministère de la santé et des services sociaux du Québec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name><affiliation wicri:level="3"><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>British Columbia Centre for Disease Control, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="Ouakki, Manale" sort="Ouakki, Manale" uniqKey="Ouakki M" first="Manale" last="Ouakki">Manale Ouakki</name><affiliation wicri:level="1"><nlm:affiliation>Institut national de santé publique du Québec, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institut national de santé publique du Québec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Lacroix, Kevin" sort="Lacroix, Kevin" uniqKey="Lacroix K" first="Kevin" last="Lacroix">Kevin Lacroix</name><affiliation wicri:level="1"><nlm:affiliation>CHU de Québec, Quebec , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CHU de Québec, Quebec </wicri:regionArea><wicri:noRegion>Quebec </wicri:noRegion></affiliation></author><author><name sortKey="Bedard, Fernand" sort="Bedard, Fernand" uniqKey="Bedard F" first="Fernand" last="Bédard">Fernand Bédard</name><affiliation wicri:level="1"><nlm:affiliation>CHU de Québec, Quebec , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CHU de Québec, Quebec </wicri:regionArea><wicri:noRegion>Quebec </wicri:noRegion></affiliation></author><author><name sortKey="Toth, Eveline" sort="Toth, Eveline" uniqKey="Toth E" first="Eveline" last="Toth">Eveline Toth</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Ministère de la santé et des services sociaux du Québec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Ministère de la santé et des services sociaux du Québec, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Dupre, Nicolas" sort="Dupre, Nicolas" uniqKey="Dupre N" first="Nicolas" last="Dupré">Nicolas Dupré</name><affiliation wicri:level="4"><nlm:affiliation>Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec </wicri:regionArea><orgName type="university">Université Laval</orgName><placeName><settlement type="city">Québec (ville)</settlement><region type="state">Québec</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Child (MeSH)</term><term>Drug Combinations (MeSH)</term><term>Europe (epidemiology)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Paresthesia (chemically induced)</term><term>Paresthesia (epidemiology)</term><term>Polysorbates (administration & dosage)</term><term>Polysorbates (adverse effects)</term><term>Quebec (epidemiology)</term><term>Risk Factors (MeSH)</term><term>Squalene (administration & dosage)</term><term>Squalene (adverse effects)</term><term>Young Adult (MeSH)</term><term>alpha-Tocopherol (administration & dosage)</term><term>alpha-Tocopherol (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Association médicamenteuse (MeSH)</term><term>Enfant (MeSH)</term><term>Europe (épidémiologie)</term><term>Facteurs de risque (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (virologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Paresthésie (induit chimiquement)</term><term>Paresthésie (épidémiologie)</term><term>Polysorbates (administration et posologie)</term><term>Polysorbates (effets indésirables)</term><term>Québec (épidémiologie)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Squalène (administration et posologie)</term><term>Squalène (effets indésirables)</term><term>Sujet âgé (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>alpha-Tocophérol (administration et posologie)</term><term>alpha-Tocophérol (effets indésirables)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Polysorbates</term><term>Squalene</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Polysorbates</term><term>Squalene</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Combinations</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Europe</term><term>Quebec</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Polysorbates</term><term>Squalène</term><term>Vaccins antigrippaux</term><term>alpha-Tocophérol</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Paresthesia</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Polysorbates</term><term>Squalène</term><term>Vaccins antigrippaux</term><term>alpha-Tocophérol</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Paresthesia</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Paresthésie</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Europe</term><term>Paresthésie</term><term>Québec</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Case-Control Studies</term><term>Child</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association médicamenteuse</term><term>Enfant</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Sujet âgé</term><term>Études cas-témoins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Paresthesia was the third-most-common adverse event following immunization (AEFI) with 2009 monovalent AS03-adjuvanted A(H1N1)pdm09 vaccine in Quebec, Canada and was also frequently reported in Europe. This study assessed clinical features and risk factors associated with this unexpected AEFI.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Reports to the passive surveillance system were summarized. A case-control study was conducted to assess risk factors and additional investigations were undertaken among cases with symptoms persisting ≥12 months.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>There were 328 reports of paresthesia affecting the vaccinated arm (58%), but also face (45%), lower limbs (40%) and back/thorax (23%) with numbness but also muscle weakness (61%), motor impairment (61%), generalized myalgia (37%), visual (14%) and/or speech effects (15%). Reporting rate was highest in women of reproductive age, peaking at 30-39 years-old (28/100,000 doses administered) and exceeding that of men of the same age (7/100,000 doses) by 4-fold. Median time to onset was 2h. Symptoms subsided within one week in 37% but lasted ≥6 months in 26%. No consistent or objective neurological findings were identified. Risk was increased with allergy history, respiratory illness the day of vaccination, depressive symptoms and family history of pulmonary disease, but decreased with physical activity the day of vaccination, and regular weekly alcohol consumption.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Paresthesia following 2009 pandemic vaccine receipt lasted several weeks and included other motor-sensory disturbances in an important subset of patients. Although it does not correspond with known neurological disease, and causality remains uncertain, further investigation is warranted to understand the nature and frequency of paresthesia as a possible AEFI with influenza vaccines.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26209839</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>36</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.</ArticleTitle><Pagination><MedlinePgn>4464-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2015.07.028</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(15)00972-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Paresthesia was the third-most-common adverse event following immunization (AEFI) with 2009 monovalent AS03-adjuvanted A(H1N1)pdm09 vaccine in Quebec, Canada and was also frequently reported in Europe. This study assessed clinical features and risk factors associated with this unexpected AEFI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Reports to the passive surveillance system were summarized. A case-control study was conducted to assess risk factors and additional investigations were undertaken among cases with symptoms persisting ≥12 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 328 reports of paresthesia affecting the vaccinated arm (58%), but also face (45%), lower limbs (40%) and back/thorax (23%) with numbness but also muscle weakness (61%), motor impairment (61%), generalized myalgia (37%), visual (14%) and/or speech effects (15%). Reporting rate was highest in women of reproductive age, peaking at 30-39 years-old (28/100,000 doses administered) and exceeding that of men of the same age (7/100,000 doses) by 4-fold. Median time to onset was 2h. Symptoms subsided within one week in 37% but lasted ≥6 months in 26%. No consistent or objective neurological findings were identified. Risk was increased with allergy history, respiratory illness the day of vaccination, depressive symptoms and family history of pulmonary disease, but decreased with physical activity the day of vaccination, and regular weekly alcohol consumption.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Paresthesia following 2009 pandemic vaccine receipt lasted several weeks and included other motor-sensory disturbances in an important subset of patients. Although it does not correspond with known neurological disease, and causality remains uncertain, further investigation is warranted to understand the nature and frequency of paresthesia as a possible AEFI with influenza vaccines.</AbstractText><CopyrightInformation>Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Serres</LastName><ForeName>Gaston</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut national de santé publique du Québec, Quebec, Canada; Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec , Canada. Electronic address: gaston.deserres@inspq.qc.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skowronski</LastName><ForeName>Danuta M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouakki</LastName><ForeName>Manale</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut national de santé publique du Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>CHU de Québec, Quebec , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bédard</LastName><ForeName>Fernand</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CHU de Québec, Quebec , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Eveline</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landry</LastName><ForeName>Monique</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ministère de la santé et des services sociaux du Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupré</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Laval University, Quebec, Canada; CHU de Québec, Quebec , Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C550253">ASO3B adjuvant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical><Chemical><RegistryNumber>H4N855PNZ1</RegistryNumber><NameOfSubstance UI="D024502">alpha-Tocopherol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010292" MajorTopicYN="N">Paresthesia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011792" MajorTopicYN="N" Type="Geographic">Quebec</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024502" MajorTopicYN="N">alpha-Tocopherol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjuvanted vaccine</Keyword><Keyword MajorTopicYN="N">Adverse event</Keyword><Keyword MajorTopicYN="N">Influenza vaccine</Keyword><Keyword MajorTopicYN="N">Neurological</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26209839</ArticleId><ArticleId IdType="pii">S0264-410X(15)00972-X</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2015.07.028</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Colombie-Britannique</li><li>Québec</li></region><settlement><li>Québec (ville)</li><li>Vancouver</li></settlement><orgName><li>Université Laval</li></orgName></list><tree><country name="Canada"><region name="Québec"><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name></region><name sortKey="Bedard, Fernand" sort="Bedard, Fernand" uniqKey="Bedard F" first="Fernand" last="Bédard">Fernand Bédard</name><name sortKey="Dupre, Nicolas" sort="Dupre, Nicolas" uniqKey="Dupre N" first="Nicolas" last="Dupré">Nicolas Dupré</name><name sortKey="Lacroix, Kevin" sort="Lacroix, Kevin" uniqKey="Lacroix K" first="Kevin" last="Lacroix">Kevin Lacroix</name><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name><name sortKey="Ouakki, Manale" sort="Ouakki, Manale" uniqKey="Ouakki M" first="Manale" last="Ouakki">Manale Ouakki</name><name sortKey="Rouleau, Isabelle" sort="Rouleau, Isabelle" uniqKey="Rouleau I" first="Isabelle" last="Rouleau">Isabelle Rouleau</name><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name><name sortKey="Toth, Eveline" sort="Toth, Eveline" uniqKey="Toth E" first="Eveline" last="Toth">Eveline Toth</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000207 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000207 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26209839
|texte= Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26209839" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |